Palatin Technologies

Palatin Technologies(PTN)

CRANBURY, NJ
Biotechnology

Focus: Small Molecules

Palatin Technologies is a life sciences company focused on Small Molecules.

OphthalmologyCardiovascularRespiratoryNephrologyImmunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Phase 2
Bremelanotide
Kidney Disease
Phase 2
Clinical Trials (1)
NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Phase 2
PL8177 Placebo
Ulcerative Colitis
Phase 2
Clinical Trials (1)
NCT05466890Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
Phase 2
Phase 2
Clinical Trials (1)
NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Phase 2
PL-3994 Aqueous Intravenous Solution Dose Ascention
Heart Failure With Preserved Ejection Fraction
Phase 2
Clinical Trials (1)
NCT04318145Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
Phase 2
PL-3994
Asthma
Phase 2
Clinical Trials (1)
NCT01304628Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
Phase 2
bremelanotide
Obesity
Phase 2
Clinical Trials (1)
NCT06565611A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Phase 2
PL9643 Ophthalmic Solution
Dry Eye Disease
Phase 2
Clinical Trials (1)
NCT04268069Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
Phase 2
Phase 2
Clinical Trials (1)
NCT00686803Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension
Phase 2
Clinical Trials (1)
NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Phase 3
Vehicle Ophthalmic Solution
Dry Eye
Phase 3
Clinical Trials (1)
NCT05201170A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
Phase 3
Clinical Trials (1)
NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1997
Portfolio: 11 clinical trials
SEC Filings: 2 available

Financials (FY2025)

Revenue
$4M7%
R&D Spend
$22M(499%)1%
Net Income
-$30M
Cash
$3M